On 21 May 2015, orphan designation (EU/3/15/1497) was granted by the European Commission to Prana Biotechnology UK Limited, United Kingdom, for 5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride for the treatment of Huntington's disease.
The sponsorship was transferred to Drug Development and Regulation S.L., Spain, in April 2019.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in November 2019 on request of the Sponsor.
|Disease / condition||
Treatment of Huntington’s disease
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.